Industry Collaborations - Past Events
Previous seminars
Title: Intellectual Property (IP)
The Swedish Intellectual Property Office - PRV representative Carl Hamsten discussed how to create value around IP as a researcher. Then Hans-Gustaf Ljunggren presented examples of IP and Richard Cowburn discussed things to consider when collaborating with industry.
Date and Time: 4th of September 2024, 13:30-15:30 (Fika included)
Location: Peter Reichard, Biomedcium, Solna Campus
Agenda:
13.30 – 13:40 Welcoming words, Simon Ekman, Leader of the Industry Collaboration Working Group Cancer Research KI
13.40 – 14:20 "How to create value around IP as a researcher" Carl Hamsten, PRV
14.20 – 14.40 "Experiences from starting up companies based on generated IP and academic-industrial collaborations at large", Hans-Gustaf Ljunggren, KI
14.40 – 14.55 Things to consider when collaborating with industry, Richard Cowburn, KI
14.55 – 15.30 Panel discussion and answers to questions
Title: Why and how to collaborate with industry
Date and TIme: 5th of February 2024, 12:00-14:00 (lunch included)
Location: Ragnar Granit, Biomedcium, Solna Campus
Agenda:
12.00 Welcoming words, Simon Ekman Leader of the Industry Collaboration working group Cancer Research KI
12.10 Why and how to collaborate with industry? Richard Cowburn and External Engagement office
12.40 High-level examples of oncology companies from KI
12:40-13:00 Thomas Helleday, SciLifeLab, “From conceptualizing a cancer treatment to approved first line therapy - pitfalls and lucky strikes”.
13:00-13:20 Mattias Rantalainen, "Bringing an AI-based precision diagnostic solution from academic research to a deployed medical device in clinic".
13:20-13:40 Hans Grönlund, "The Neogap story".
13.40 Q&A
14.00 Conclusions and final remarks
Programme for the seminar on the 23rd of March, 2023
Time: 13.00-15.30
Topic: Collaborate with academia, the company perspective.
Venue: Inghesalen Tomtebodavägen 18a, 171 65 Solna Campus (This event Will be in person).
Programme
13.00 Welcoming words by Simon Ekman
13.10 Elypta Francesco Gatto, Chief Science officer
13.30 Arne Östman and ROADS program Roche Anton Kraxner
13.50 KI Science Park Sara Gunnerås, Community Manager
14.10 NeoGap Hans Grönlund, Chief Science officer
14.30 Fika
14.45 Sprint BioSciences Martin Andersson Chief Scientific officer
15.05 Q&A with all presenters
15.30 end of seminar
Programme for the seminar on the 5th of December, 2022, Clinical Cancer Trials with an Emphasis on Early Experimental Studies and Collaboration with the Pharmaceutical Industry and Biotech companies
Speaker: Jeffrey Yachnin, Senior Consultant Karolinska Comprehensive Cancer Center Department of Clinical Cancer Studies, Cancer Theme, Karolinska University Hospital
Venue: Inghesalen Tomtebodavägen 18a, 171 65 Solna Campus or Zoom ( a link will be sent after registration)
Welcome to the hybrid seminar organised by Cancer Research KI. There will be time to discuss and ask questions during the afternoon. Please join either via zoom or in real life where fika will be served before the meeting. Details obtained after the registration.
Programme for the seminar on the 12th of October, 2022
Venue: Scheelesalen Tomtebodavägen 6, 171 65 Solna Campus or Zoom ( a link will be sent after registration)
Welcome to the hybrid seminar organised by Cancer Research KI. Swedish Intellectual Property Office (PRV) will give a talk about about how to create value around Intellectual Property (IP) as a researcher. Hans-Gustaf Ljunggren will present a couple of examples of IP.
13.00 - 13.45 "How to create value around IP as a researcher" Carl Hamsten
13.45 - 14.00 Examples by a researcher, Hans-Gustaf Ljunggren
14.00 -14.15 KI perspective, Richard Cowburn (how to deal with confidentiality, teachers perspective)
14.15 - 15.00 Panel discussion and answers to questions
Programme for the seminar on the 19th of May, 2022, KI/Merck: existing and potential collaborations
During this seminar, you will learn how Merck is looking to expand their ongoing collaboration with KI in the areas of oncology and immuno-oncology. An ongoing project will also be presented. There will be time to discuss and ask questions during the afternoon.
13.45-14.00 : Coffee and networking
14.00-14.10 : Welcome and Introduction Simon Ekman (Cancer Research KI) and Sven Pötzsch (Merck Healthcare KGaA)
14.10- 14.30 : Richard Cowburn (KI) KI perspectives on Industry/Academia Partnerships the research area of Oncology
14.30- 14.50 : Kahina Lang (Merck Healthcare KGaA) Strategic Innovation at Merck: Motivation and Mission
14.50- 14.55: Short break
14.55- 15.15 : Eike-Benjamin Braune (KI) Modulation of NOTCH Signaling as a new treatment option for solid tumors
15.15- 15.35 : Felix Geist (Merck Healthcare KGaA) Identification of a NOTCH transcriptomic signature for basal like breast cancer
15.35-15.55: Simon Ekman (Cancer Research KI), Richard Cowburn (KI) and Sven Pötzsch (Merck Healthcare KGaA) Open discussion
15.55: Closing remarks Simon Ekman
Programme for the seminar on January 20th, 2022
13.00 Welcoming words: Simon Ekman Leader of the Industrial collaboration working group CRKI
13.10 Why collaborate with industry? High-level examples of industrial relations KI have established within oncology: Richard Cowburn
14.00 Short break
14.10 KI processes and ways of working with industry: Richard Cowburn and External Engagement office
15.00 Conclusions and final remarks
Mentor4Research (M4R): a new mentorship program for researchers at KI
Open Mentor4Research (M4R) Program configuration options
Mentor4Research (M4R) program is aimed at researchers who are interested in learning more about the commercialization or implementation of research and collaborating with the business community.
Merck-KI Science Day 2019
Karolinska Institutet and Merck KGaA, Germany, currently run several joint projects in the fields of oncology, immuno-oncology and immunology. The current oncology/ immuno-oncology projects are headed at KI by Randall Johnson, Urban Lendahl and Evren Alici.
A first Merck-KI Science Day took place at the Merck headquarters in Darmstadt Feb. 12th, 2019 to strengthen the current collaboration and allow for discussion regarding new joint projects.
KI-Roche WS 2015
KI and Roche had an active Master Collaborative Agreement (MCA) for strategic collaboration in the Cancer Research field (signed by KI and Roche global research organization in December 2014) during 2015-17. The aim of the agreement was to develop new and better therapies and more specific methods for analyses, as well as to identify novel signal pathways as potential drug targets. The MCA was featured in a news article in LIFe-time.se.
A joint KI-Roche workshop in Oncology was held at Nobel Forum KI Solna October 19-20, 2015 with the ambition to allow interaction and discussion regarding possibilities for joint research projects.
The Joint Steering Committee (JSC)* met regularly during the agreement period. It was jointly agreed not to prolongue the MCA, but to continue a dialogue and interaction around potentielly interesting collaborative projects.
* JSC Members: Astrid Kiermaier (Roche), Pavel Pisa (Roche), Rune Toftgård (KI), Klas Wiman (KI), Chair: Gabriele Beer (Roche). Alliance Directors: Björn Arvidsson (Roche) and Sandra Falck (KI).